Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 255-263

  Wilkinson, Royce A ^a   Pincus, Seth H ^b,c   Shepard, Joyce B ^a   Walton, Sarah K ^a   Bergin, Edward P ^a   Labib, Mohamed ^d   Teintze, Martin ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Novaflux Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; BIGUANIDE DERIVATIVE; CHEMOKINE RECEPTOR CXCR4; GUANIDE DERIVATIVE; GUANIDINE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PHENYLGUANIDE DERIVATIVE; SPERMIDINE PHENYLGUANIDE; SPERMINE PHENYLGUANIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS STRAIN;

ANTI-HIV AGENTS; CELL LINE; HIV-1; HUMANS; PEPTIDES; RECEPTORS, CXCR4;

EID: 78650660896     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00709-10     Document Type: Article

References (41)

1. Babcock, G. J., T. Mirzabekov, W. Wojtowicz, and J. Sodroski. 2001. Ligand binding characteristics of CXCR4 incorporated into paramagnetic proteoliposomes. J. Biol. Chem. 276:38433-38440.
2. Billick, E., C. Seibert, P. Pugach, T. Ketas, A. Trkola, M. J. Endres, N. J. Murgolo, E. Coates, G. R. Reyes, B. M. Baroudy, T. P. Sakmar, J. P. Moore, and S. E. Kuhmann. 2004. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J. Virol. 78:4134-4144.
3. Catalone, B. J., T. M. Kish-Catalone, L. R. Budgeon, E. B. Neely, M. Ferguson, F. C. Krebs, M. K. Howett, M. Labib, R. Rando, and B. Wigdahl. 2004. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob. Agents Chemother. 48:1837-1847.
4. Connor, R. I., K. E. Sheridan, D. Ceradini, S. Choe, and N. R. Landau. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-628.
5. De Clercq, E. 2009. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem. Pharmacol. 77:1655-1664.
6. Donzella, G. A., D. Schols, S. W. Lin, J. A. Este, K. A. Nagashima, P. J. Maddon, G. P. Allaway, T. P. Sakmar, G. Henson, E. De Clercq, and J. P. Moore. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor. Nat. Med. 4:72-77.
7. Doranz, B. J., L. G. Filion, F. Diaz-Mitoma, D. S. Sitar, J. Sahai, F. Baribaud, M. J. Orsini, J. L. Benovic, W. Cameron, and R. W. Doms. 2001. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res. Hum. Retrovir. 17:475-486.
8. Doranz, B. J., K. Grovit-Ferbas, M. P. Sharron, S. H. Mao, M. B. Goetz, E. S. Daar, R. W. Doms, and W. A. O'Brien. 1997. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186:1395-1400.
9. Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
10. Dragic, T., A. Trkola, D. A. Thompson, E. G. Cormier, F. A. Kajumo, E. Maxwell, S. W. Lin, W. Ying, S. O. Smith, T. P. Sakmar, and J. P. Moore. 2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U. S. A. 97:5639-5644.
11. Eilingsfeld, H., and H. Scheuermann. 1967. Synthese Von 1.3.5-Triazinen. Chemische Berichte-Recueil. 100:1874-1891.
12. Fujii, N., S. Oishi, K. Hiramatsu, T. Araki, S. Ueda, H. Tamamura, A. Otaka, S. Kusano, S. Terakubo, H. Nakashima, J. Broach, J. Trent, Z. Wang, and S. Peiper. 2003. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew. Chem. Int. 42:3251-3253.
13. Gerlach, L. O., R. T. Skerlj, G. J. Bridger, and T. W. Schwartz. 2001. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 276:14153-14160.
14. Hatse, S., K. Princen, E. De Clercq, M. M. Rosenkilde, T. W. Schwartz, P. E. Hernandez-Abad, R. T. Skerlj, G. J. Bridger, and D. Schols. 2005. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem. Pharmacol. 70:752-761.
15. Hatse, S., K. Princen, L. O. Gerlach, G. Bridger, G. Henson, E. De Clercq, T. W. Schwartz, and D. Schols. 2001. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol. Pharmacol. 60:164-173.
16. Hendrix, C. W., A. C. Collier, M. M. Lederman, D. Schols, R. B. Pollard, S. Brown, J. B. Jackson, R. W. Coombs, M. J. Glesby, C. W. Flexner, G. J. Bridger, K. Badel, R. T. MacFarland, G. W. Henson, and G. Calandra. 2004. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 37:1253-1262.
17. Ichiyama, K., S. Yokoyama-Kumakura, Y. Tanaka, R. Tanaka, K. Hirose, K. Bannai, T. Edamatsu, M. Yanaka, Y. Niitani, N. Miyano-Kurosaki, H. Takaku, Y. Koyanagi, and N. Yamamoto. 2003. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U. S. A. 100:4185-4190.
18. Kaiser, D. W., J. T. Thurston, J. R. Dudley, F. C. Schaefer, I. Hechenbleikner, and D. Holmhansen. 1951. Cyanuric chloride derivatives. 2. Substituted melamines. J. Am. Chem. Soc. 73:2984-2986.
19. Ketas, T. J., S. M. Schader, J. Zurita, E. Teo, V. Polonis, M. Lu, P. J. Klasse, and J. P. Moore. 2007. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 364:431-440.
20. Krebs, F. C., S. R. Miller, M. L. Ferguson, M. Labib, R. F. Rando, and B.Wigdahl. 2005. Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1. Biomed. Pharmacother. 59:438-445.
21. Krowicka, H., J. Robinson, R. Clark, S. Hager, S. Broyles, and S. Pincus. 2008. Use of tissue culture cell lines to evaluate HIV antiviral resistance. AIDS Res. Hum. Retrovir. 24:957-967.
22. Moyle, G., E. DeJesus, M. Boffito, R. Wong, C. Gibney, K. Badel, R. Mac-Farland, G. Calandra, G. Bridger, S. Becker, et al. 2009. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin. Infect. Dis. 48:798-805.
23. Muller, D., I. Zeltser, G. Bitan, and C. Gilon. 1997. Building units for N-backbone cyclic peptides. 3. Synthesis of protected N-α-(omega- aminoalkyl) amino acids and N-α-(omega-carboxyalkyl) amino acids. J. Organic Chem. 62:411-416.
24. Murakami, T., A. Yoshida, R. Tanaka, S. Mitsuhashi, K. Hirose, M. Yanaka, N. Yamamoto, and Y. Tanaka. 2004. KRH-2731: an orally bioavailable CXCR4 antagonist is a potent inhibitor of HIV-1 infection. Top. HIV Med. 12:541.
25. Narumi, T., R. Hayashi, K. Tomita, K. Kobayashi, N. Tanahara, H. Ohno, T. Naito, E. Kodama, M. Matsuoka, S. Oishi, and N. Fujii. 2010. Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres. Org. Biomol. Chem. 8:616-621.
26. Rosenkilde, M. M., L. O. Gerlach, S. Hatse, R. T. Skerlj, D. Schols, G. J. Bridger, and T. W. Schwartz. 2007. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J. Biol. Chem. 282:27354-27365.
27. Seibert, C., and T. P. Sakmar. 2004. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr. Pharm. Des. 10:2041-2062.
28. Seibert, C., W. Ying, S. Gavrilov, F. Tsamis, S. E. Kuhmann, A. Palani, J. R. Tagat, J. W. Clader, S. W. McCombie, B. M. Baroudy, S. O. Smith, T. Dragic, J. P. Moore, and T. P. Sakmar. 2006. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349:41-54.
29. Skerlj, R., G. Bridger, A. Kaller, E. McEachern, J. Crawford, Y. Zhou, B. Atsma, J. Langille, S. Nan, D. Veale, T. Wilson, C. Harwig, S. Hatse, K. Princen, E. De Clercq, and D. Schols. 2010. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J. Med. Chem. 53: 3376-3388.
30. Tamamura, H., K. Hiramatsu, S. Kusano, S. Terakubo, N. Yamamoto, J. O. Trent, Z. Wang, S. C. Peiper, H. Nakashima, A. Otaka, and N. Fujii. 2003. Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives. Org. Biomol. Chem. 1:3656-3662.
31. Tamamura, H., M. Sugioka, Y. Odagaki, A. Omagari, Y. Kan, S. Oishi, H. Nakashima, N. Yamamoto, S. C. Peiper, N. Hamanaka, A. Otaka, and N. Fujii. 2001. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg. Med. Chem. Lett. 11:359-362.
32. Tamamura, H., Y. Xu, T. Hattori, X. Zhang, R. Arakaki, K. Kanbara, A. Omagari, A. Otaka, T. Ibuka, N. Yamamoto, H. Nakashima, and N. Fujii. 1998. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. 253:877-882.
33. Thakkar, N., V. Pirrone, S. Passic, S. Keogan, W. Zhu, V. Kholodovych, W. Welsh, R. Rando, M. Labib, B. Wigdahl, and F. Krebs. 2010. Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection. Antimicrob. Agents Chemother. 54:1965-1972.
34. Thakkar, N., V. Pirrone, S. Passic, W. Zhu, V. Kholodovych, W. Welsh, R. Rando, M. Labib, B. Wigdahl, and F. Krebs. 2009. Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection. Antimicrob. Agents Chemother. 53:631-638.
35. Tsamis, F., S. Gavrilov, F. Kajumo, C. Seibert, S. Kuhmann, T. Ketas, A. Trkola, A. Palani, J. W. Clader, J. R. Tagat, S. McCombie, B. Baroudy, J. P. Moore, T. P. Sakmar, and T. Dragic. 2003. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77:5201-5208.
36. Ueda, S., M. Kato, S. Inuki, H. Ohno, B. Evans, Z. X. Wang, S. C. Peiper, K. Izumi, E. Kodama, M. Matsuoka, H. Nagasawa, S. Oishi, and N. Fujii. 2008. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg. Med. Chem. Lett. 18:4124-4129.
37. Ueda, S., S. Oishi, Z. X. Wang, T. Araki, H. Tamamura, J. Cluzeau, H. Ohno, S. Kusano, H. Nakashima, J. O. Trent, S. C. Peiper, and N. Fujii. 2007. Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side chain and backbone functionalities. J. Med. Chem. 50:192-198.
38. Vaillancourt, V. A., S. D. Larsen, S. P. Tanis, J. E. Burr, M. A. Connell, M. M. Cudahy, B. R. Evans, P. V. Fisher, P. D. May, M. D. Meglasson, D. D. Robinson, F. C. Stevens, J. A. Tucker, T. J. Vidmar, and J. H. Yu. 2001. Synthesis and biological activity of aminoguanidine and diaminoguanidine analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid. J. Med. Chem. 44:1231-1248.
39. Wagner, T. A., and L. M. Frenkel. 2008. Potential limitation of CCR5 antagonists: drug resistance more often linked to CXCR4-utilizing than to CCR5-utilizing HIV-1. AIDS 22:2393-2395.
40. Watson, C., S. Jenkinson, W. Kazmierski, and T. Kenakin. 2005. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67:1268-1282.
41. Wei, X., J. Decker, H. Liu, Z. Zhang, R. Arani, J. Kilby, M. Saag, X. Wu, G. Shaw, and J. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.